Source: Annual Congress 2010 - Experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Bilan, S. Tofovic (United States Of America). Two rat models of hemolysis-induced pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1071

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Reversibility of the monocrotaline pulmonary hypertension rat model Source: Eur Respir J 2013; 42: 553-556 Year: 2013 A novel murine model of severe pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020 Year: 2021 Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 365s Year: 2005 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction Source: Eur Respir J 2014; 44: 160-168 Year: 2014 Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 An investigation of the origins of pulmonary artery lesion cells in pulmonary arterial hypertension rat models Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Formation of typical vascular lesions in a new experimental model of pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017